Homepage

Thermo Fisher Scientific Inc.

TMO NYSE Categories PDF
Healthcare · Medical - Diagnostics & Research
Waltham, MA 02451, United States IPO 1980 thermofisher.com Updated Jun 27, 3:13am
Price
$513.03
Market Cap
$190.7B
Employees
125,000
Beta
0.87
Avg Volume
2,218,420
CEO
Marc N. Casper
Business Description

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.

Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Jun 21, 2026 6:52pm (5d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 6:52pm (5d ago)
Metric 2021 2022 2023 2024 2025
Revenue $39.2B $44.9B $42.9B $42.9B $44.6B
Cost of Revenue $19.6B $25.9B $25.7B $25.2B $27.8B
Gross Profit $19.6B $19.0B $17.2B $17.7B $16.8B
Operating Expenses $9.3B $10.5B $9.7B $10.1B $8.7B
Operating Income $10.3B $8.5B $7.4B $7.7B $8.1B
Net Income $7.7B $7.0B $6.0B $6.3B $6.7B
EBITDA $12.0B $11.9B $11.2B $11.8B $11.5B
EPS $19.61 $17.73 $15.53 $16.58 $17.77
EPS (Diluted)
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:52pm (5d ago)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $4.5B $8.5B $8.1B $4.0B $9.9B
Total Current Assets $20.1B $25.2B $24.6B $22.1B $28.7B
Total Assets $95.1B $97.2B $98.7B $97.3B $110.3B
Current Liabilities $13.4B $17.0B $14.0B $13.3B $15.2B
Long-Term Debt $32.1B $28.9B $31.3B $29.1B $35.9B
Total Liabilities $54.1B $53.0B $51.9B $47.7B $56.8B
Total Equity $40.8B $44.0B $46.7B $49.6B $53.4B
Retained Earnings $35.4B $41.9B $47.4B $53.1B $59.2B
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:52pm (5d ago)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $9.5B $9.2B $8.4B $8.7B $7.8B
Capital Expenditure -$2.5B -$2.2B -$1.5B -$1.4B -$1.5B
Free Cash Flow $7.0B $6.9B $6.9B $7.3B $6.3B
Acquisitions (net) -$19.4B -$39.0M -$3.7B -$3.1B -$4.0B
Debt Repayment
Dividends Paid
Stock Buybacks -$2.0B -$3.0B -$3.0B -$4.0B -$3.0B
Net Change in Cash -$5.8B $4.0B -$440.0M -$4.1B $5.8B
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:52pm (5d ago)
Metric 2022 2023 2024 2025
Revenue Growth +14.5% -4.6% +0.1% +3.9%
Gross Profit Growth -3.2% -9.6% +3.1% -5.4%
Operating Income Growth -17.4% -12.7% +2.9% +5.8%
Net Income Growth -10.0% -13.7% +5.7% +6.3%
EBITDA Growth -0.2% -6.3% +5.4% -2.8%
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:52pm (5d ago)
Date Dividend Declaration Record Payment
2026-06-15 $0.47 2026-05-20 2026-06-15 2026-07-15
2026-03-13 $0.47 2026-02-25 2026-03-13 2026-04-15
2025-12-15 $0.43 2025-11-06 2025-12-15 2026-01-15
2025-09-15 $0.43 2025-07-10 2025-09-15 2025-10-15
2025-06-13 $0.43 2025-05-21 2025-06-13 2025-07-15
2025-03-14 $0.43 2025-02-19 2025-03-14 2025-04-15
2024-12-13 $0.39 2024-11-07 2024-12-13 2025-01-15
2024-09-13 $0.39 2024-07-11 2024-09-13 2024-10-15
2024-06-14 $0.39 2024-05-22 2024-06-14 2024-07-15
2024-03-14 $0.39 2024-02-21 2024-03-15 2024-04-15
2023-12-14 $0.35 2023-11-09 2023-12-15 2024-01-16
2023-09-14 $0.35 2023-07-13 2023-09-15 2023-10-13
2023-06-14 $0.35 2023-05-24 2023-06-15 2023-07-14
2023-03-14 $0.35 2023-02-22 2023-03-15 2023-04-14
2022-12-14 $0.30 2022-11-10 2022-12-15 2023-01-16
2022-09-14 $0.30 2022-07-07 2022-09-15 2022-10-14
2022-06-14 $0.30 2022-05-18 2022-06-15 2022-07-15
2022-03-15 $0.30 2022-02-23 2022-03-16 2022-04-14
2021-12-14 $0.26 2021-11-04 2021-12-15 2022-01-14
2021-09-14 $0.26 2021-07-08 2021-09-15 2021-10-15
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for TMO — it's generated by the pipeline (market-narrative step).
Community AI Feedback
No community reviews yet for TMO. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30